Quick Answer
Coya Therapeutics, Inc. reported Net Income of -$21.23 million for fiscal year 2025.
Coya Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$21.23M | -42.6% |
| 2024 | -$14.88M | -86.3% |
| 2023 | -$7.99M | +34.8% |
| 2022 | -$12.24M | -150.3% |
| 2021 | -$4.89M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.12M | +47.4% | +65.3% |
| June 30, 2025 | -$6.09M | -110.8% | +16.6% |
| March 31, 2025 | -$7.31M | -44.6% | -81.7% |
| September 30, 2024 | -$4.02M | -17.5% | -39.1% |
| June 30, 2024 | -$2.89M | +6.6% | +42.8% |
| March 31, 2024 | -$5.05M | -84.6% | -47.6% |
| September 30, 2023 | -$3.42M | +14.9% | -10.6% |
| June 30, 2023 | -$3.10M | +9.3% | -13.1% |
- Coya Therapeutics, Inc. showed a decrease of -42.6% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, Coya Therapeutics, Inc.’s net income has declined by 333.9% (from -$4.89 million to -$21.23 million).
- The most recent figure is from Coya Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: